| Literature DB >> 33042557 |
Kashif Hussain1, Muhammad Faisal Khan2, Gul Ambreen1, Syed Shamim Raza1, Seema Irfan3, Kiren Habib4, Hasnain Zafar5.
Abstract
BACKGROUND: Antibiotic resistance (ABX-R) is alarming in lower/middle-income countries (LMICs). Nonadherence to antibiotic guidelines and inappropriate prescribing are significant contributing factors to ABX-R. This study determined the clinical and economic impacts of antibiotic stewardship program (ASP) in surgical intensive care units (SICU) of LMIC.Entities:
Keywords: Antibiotic resistance; Antibiotic stewardship program; Infectious disease pharmacist; Surgical-ICU
Year: 2020 PMID: 33042557 PMCID: PMC7542464 DOI: 10.1186/s40545-020-00272-w
Source DB: PubMed Journal: J Pharm Policy Pract ISSN: 2052-3211
Patients’ characteristics and clinical indications for antibiotic in pre-ASP and post-ASP phases-ASP
| Variable | Pre-ASP intervention ( | Post-ASP intervention ( | |
|---|---|---|---|
| Demographic characteristics | |||
| Age (years)* | 51 (11.2) | 53 (9.5) | 0.87 |
| Gender (male) | 88 (72) | 93 (74) | 0.68 |
| Comorbidities** | |||
| Cardiovascular illnesses | 21 (17) | 23 (18) | 0.86 |
| Chronic hepatobiliary illnesses | 12 (10) | 13 (10) | |
| Chronic renal illnesses | 8 (7) | 7 (6) | |
| Diabetes mellitus | 30 (24) | 32 (26) | |
| Malignancies | 0 | 0 | |
| Chronic neurological/neuropsychiatric illnesses | 3 (2) | 4 (3) | |
| Chronic respiratory illnesses | 5 (4) | 4 (3) | |
| ≥ 2 chronic medical illnesses | 8 (7) | 7 (6) | |
| No comorbid condition | 36 (29) | 35 (28) | |
| Clinical indications for antibiotics in SICU | |||
| Prophylaxis | 58 (47) | 55 (44) | 0.78 |
| Empirical | 43 (35) | 45 (36) | |
| Therapeutic | 22 (18) | 25 (20) | |
| Surgeries specialty involved | |||
| General surgery | 53 (43) | 56 (45) | 0.75 |
| Neurosurgery | 42 (34) | 40 (32) | |
| Orthopedic | 15 (12) | 18 (14) | |
| Obs/gyn | 7 (6) | 6 (5) | |
| ENT | 4 (3) | 3 (2) | |
| Vascular | 2 (2) | 2 (2) | |
SICU surgical intensive care unit, ASP antibiotic stewardship program,Obs/gyn obstetrics and gynecological, ENT ears, nose and throat, ns not significant
*Mean (SD)
**Comorbidities were coded from the World Health Organization, International Classification of Diseases, 10th revision, Clinical Modification (ICD-10) [23]
Comparison of antibiotics use in pre-ASP and post -ASP phases
| Variable | Pre-ASP intervention ( | Post-ASP intervention ( | |
|---|---|---|---|
| Total number of antibiotics doses | 4400 | 2840 | < 0.01 |
| DDDs/1000 patient-days* | |||
| Total antibiotics used | 368 | 175 | < 0.01 |
| Prophylactic antibiotics | |||
| Ceftriaxone | 450 | 120 | < 0.01 |
| Metronidazole | 280 | 110 | < 0.01 |
| Cefazolin | 228 | 60 | < 0.01 |
| Empirical and therapeutic antibiotics | |||
| Carbapenems | 540 | 420 | 0.23 |
| Piperacillin/tazobactam | 390 | 150 | < 0.01 |
| Vancomycin | 320 | 190 | < 0.01 |
| Colistin | 310 | 240 | 0.24 |
| Mean duration of antibiotics therapy (days)** | |||
| Prophylactic antibiotics | |||
| Ceftriaxone | 5.5 (2.3) | 1.8 (1.3) | < 0.01 |
| Cefazolin | 4.3 (2.7) | 1.9 (1.4) | < 0.01 |
| Metronidazole | 3.0 (2.2) | 1.5 (0.7) | < 0.01 |
| Empirical and therapeutic antibiotics | |||
| Piperacillin/tazobactam | 6.7 (3.4) | 2.7 (1.2) | < 0.01 |
| Carbapenem | 10 (3.6) | 4.4 (2.3) | < 0.01 |
| Vancomycin | 6.5 (3.7) | 3.1 (1.7) | < 0.01 |
| Colistin | 7.9 (4.6) | 4.8 (2.6) | < 0.01 |
| Other clinical measures | |||
| Length of stay in SICU (days)** | 5.2 (3.1) | 4.7 (3.0) | 0.09 |
| Mortality | 21 (17.1%) | 18 (14.4%) | 0.67 |
| Readmissions | 3.0 (2.4%) | 1.0 (0.8%) | 0.07 |
*Defined daily dose/1000 patient days; **data presented as mean (SD); SICU = surgical intensive care unit; ASP = antibiotic stewardship program
Comparison of interventions data in pre-ASP and post-ASP phases
| Variable | Pre-ASP intervention ( | Post-ASP intervention ( | |
|---|---|---|---|
| Pharmacist interventions | None | 78 (62.4) | |
| Selection of antibiotic as per guidelines | 52 (42) | 94 (75) | < 0.01 |
| Duration of therapy > 5 days | 93 (76) | 17 (14) | < 0.01 |
| Source-control-documentation | None | 62 (49.6) | – |
ASP antibiotic stewardship program; Pharmacist interventions dose optimization/drug interactions/levels monitoring
Appropriateness of antibiotic prescriptions in pre-ASP and post-ASP phases
| Parameters of appropriateness of antibiotic use | Pre-ASP intervention ( | Post-ASP intervention ( | |
|---|---|---|---|
| Selection of right antibiotics to target pathogens | 52 (42) | 94 (75) | < 0.01 |
| Use of most optimum doses | 30 (24) | 109 (87) | < 0.01 |
| Blood levels concentration monitoring | 15 (12) | 100 (80) | < 0.01 |
| Drug-interactions | 32 (26) | 15 (12) | < 0.01 |
| De-escalation/discontinuation of antibiotics based on definitive diagnosis after 48-h | 25 (20) | 120 (96) | < 0.01 |
Single patient might appear in no, one or more than one parameter
Antibiotics stewardship programme (ASP) related cost breakdown in pre-ASP and post-ASP phases
| Variable | Pre-ASP intervention | Post-ASP intervention | ||||
|---|---|---|---|---|---|---|
| Unit cost (US$) | Quantity | Total cost (US$) | Unit cost (US$) | Quantity | Total cost (US$) | |
| Direct cost | ||||||
| Physician cost (hours) | – | – | – | |||
Education Consultation Feedback | 25 | 180 | 4500 | |||
| Microbiologist cost (hours) | – | – | – | |||
Data collection Susceptibility reporting | 12 | 90 | 1080 | |||
| Pharmacist cost (hours) | – | – | – | |||
Data collection and analysis Interventions | 5 | 215 | 1075 | |||
| Administrative cost for ASP designing, implementing, monitoring and evaluating (hours) | – | – | – | 30 | 50 | 1500 |
| Indirect cost | ||||||
| Pharmacy time (hours) | ||||||
| Pharmacist order processing | 3 | 200 | 600 | 3 | 80 | 240 |
| Technician (preparation and dispensing | 2 | 400 | 800 | 2 | 190 | 380 |
| Medication administration nurses time (hours) | 2.5 | 750 | 1875 | 2.5 | 396 | 990 |
| Consumables and logistics related to IV ABXs administration | 1.5 | 4400 | 6600 | 1.5 | 2840 | 4260 |
| SICU bed per day cost | 540 | 5.2* | 2808 | 540 | 4.7* | 2538 |
*Mean length of SICU stay (day); The same brands of all the antibiotics were purchased and used throughout the study in pre and post phases
Summary of ASP related cost in 4 months period in SICU unit (n = 125)
| Variables | Post-ASP Implementation | Pre-ASP Implementation | Net cost saving |
|---|---|---|---|
| Direct ASP costs (US$) | 8155 | 0.0 | 8155 |
| Indirect ASP costs (US$) | 8408 | 12,683 | − 4275 |
| ABXs cost/4 months (US$) | 14,000 | 20,000 | − 6000 |
| Net ASP cost/4 months (US$) | 30,563 | 32,683 | − 2120 |
| Net ASP cost/year (US$) | 91,689 | 98,049 | − 6360 |
The same brands of all the antibiotics were purchased and used throughout the study in pre and post phases